A 35-year-old woman with cystic fibrosis (CF) and chronic pancreatic insufficiency presents with progressive bone pain, muscle weakness, and recurrent fractures despite calcium supplementation. Serum 25-hydroxyvitamin D is 15 ng/mL (normal 30–100), alkaline phosphatase is elevated at 95 U/L, and X-ray shows osteoporosis. She reports fat-soluble stool (steatorrhea) and takes pancreatic enzyme replacement therapy. Which vitamin deficiency is the primary driver of her bone disease, and what is the biochemical mechanism?

Explanation

## Clinical Context This patient has cystic fibrosis with pancreatic insufficiency, leading to fat malabsorption (steatorrhea). All fat-soluble vitamins are at risk, but her bone disease — osteoporosis, elevated alkaline phosphatase, and hypocalcemia — is pathognomonic for **vitamin D deficiency**. ## Why Vitamin D Is the Primary Driver **Key Point:** Vitamin D (cholecalciferol, D3) is the master regulator of calcium homeostasis and bone mineralization. Its active metabolite, 1,25-dihydroxyvitamin D (calcitriol), is essential for: 1. **Intestinal calcium absorption** — increases expression of calbindin and calcium channels in enterocytes. 2. **Renal calcium reabsorption** — enhances distal tubule reabsorption. 3. **Bone mineralization** — promotes osteoblast differentiation and alkaline phosphatase expression. 4. **PTH regulation** — negative feedback suppresses secondary hyperparathyroidism. **High-Yield:** In CF with pancreatic insufficiency: - Impaired fat absorption → deficient vitamin D intake and absorption. - Low 25-OH vitamin D (the storage form) → reduced substrate for 1,25-dihydroxylation in the kidney. - Low 1,25-dihydroxyvitamin D → impaired intestinal calcium absorption → hypocalcemia → secondary hyperparathyroidism → bone resorption and osteoporosis. ## Biochemical Mechanism ```mermaid flowchart TD A[Cystic Fibrosis<br/>Pancreatic Insufficiency]:::outcome --> B[Impaired Fat Absorption<br/>Steatorrhea]:::outcome B --> C[Vitamin D Malabsorption]:::outcome C --> D[Low 25-OH Vitamin D]:::outcome D --> E[Reduced 1,25-Dihydroxylation<br/>in Kidney]:::action E --> F[Low 1,25-Dihydroxyvitamin D]:::outcome F --> G{Intestinal Calcium<br/>Absorption?}:::decision G -->|Decreased| H[Hypocalcemia]:::urgent H --> I[Secondary Hyperparathyroidism]:::outcome I --> J[Increased Bone Resorption]:::action J --> K[Osteoporosis<br/>Recurrent Fractures]:::urgent ``` **Clinical Pearl:** The serum 25-hydroxyvitamin D level of 15 ng/mL is **severely deficient** (normal ≥30 ng/mL). This is the best marker of vitamin D status and directly reflects hepatic storage and activation capacity. ## Why Not the Other Vitamins? | Vitamin | Role in Bone | Deficiency Presentation | Relevance to This Case | |---------|--------------|------------------------|------------------------| | **A** | Osteoid matrix formation, osteoclast regulation | Impaired fracture healing, but NOT osteoporosis or hypocalcemia | Bone pain is from hypocalcemia, not matrix defect | | **D** | **Calcium absorption, mineralization, PTH regulation** | **Osteoporosis, hypocalcemia, elevated ALP, secondary HPT** | **MATCHES THIS CASE EXACTLY** | | **E** | Antioxidant (minor role in bone) | Neurologic symptoms, not bone disease | Does not cause osteoporosis or hypocalcemia | | **K** | Osteocalcin γ-carboxylation (bone matrix protein) | Impaired bone quality, but NOT hypocalcemia or secondary HPT | Osteocalcin deficiency does not cause calcium malabsorption | **Mnemonic for vitamin D metabolism:** - **Skin (7-dehydrocholesterol)** → UV-B → **Cholecalciferol (D3)** - **Liver** → 25-hydroxylase → **25-OH D (calcidiol)** [storage form, best marker] - **Kidney** → 1α-hydroxylase → **1,25-dihydroxyvitamin D (calcitriol)** [active form] - **Kidney** → 24-hydroxylase → 24,25-dihydroxyvitamin D [inactivation] ## Management 1. **Vitamin D3 supplementation** — high-dose (2000–4000 IU daily or 50,000 IU weekly) to restore 25-OH D to >30 ng/mL. 2. **Calcium supplementation** — 1000–1200 mg daily (with vitamin D for absorption). 3. **Monitor PTH and alkaline phosphatase** — should normalize as vitamin D repletes. 4. **Optimize pancreatic enzyme replacement** — improves fat absorption of all fat-soluble vitamins. 5. **Consider DEXA scan** — assess bone density and monitor response to therapy. **Warning:** Vitamin K deficiency in CF is less common than vitamin D deficiency and does not cause hypocalcemia or secondary hyperparathyroidism — it causes coagulopathy (elevated PT) and impaired bone matrix protein carboxylation, not calcium malabsorption. [cite:Harrison 21e Ch 376; KD Tripathi 8e Ch 29]